- Ticker
- ADMP
- Price
- 0.22
- Stock movement down
- -0.01 (-4.30%)
- Company name
- Adamis Pharma
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers-Specialty & Generic
- Markedsverdi
- 33.01M
- Ent verdi
- 39.88M
- Pris/omsetning
- 21.43
- Pris/bok
- 11.60
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års avkastning
- -64.50%
- 3 års avkastning
- -32.71%
- 5 års avkastning
- -42.82%
- 10 års avkastning
- -32.71%
Sist oppdatert: 2023-02-03
UTBYTTE
ADMP betaler ikke utbytte
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | 21.43 |
| Pris til bok | 11.60 |
| EV i forhold til salg | 25.89 |
ØKONOMI
Per aksje
Loading...
Per aksje-data
| Gjeldende aksje antall | 149.98M |
| EPS (TTM) | -0.21 |
| FCF per aksje (TTM) | -0.21 |
Resultatregnskap
Loading...
Resultatregnskap-data
| Inntekter (TTM) | 1.54M |
| Bruttofortjeneste (TTM) | -4.25M |
| Driftsinntekter (TTM) | -28.63M |
| Netto inntekt (TTM) | -31.92M |
| EPS (TTM) | -0.21 |
| EPS (1 år fremover) | - |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | -276.18% |
| Driftsmargin (TTM) | -1858.60% |
| Fortjenestemargin (TTM) | -2072.23% |
Balanse
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
| Kontanter | 2.42M |
| Netto fordringer | 1.55M |
| Samlede omløpsmidler | 10.09M |
| Goodwill | 0.00 |
| Immaterielle eiendeler | 0.00 |
| Eiendom, anlegg og utstyr | 0.00 |
| Sum eiendeler | 12.14M |
| Leverandørgjeld | 5.30M |
| Kortsiktig/nåværende langsiktig gjeld | 432.02K |
| Sum kortsiktig gjeld | 8.87M |
| Sum gjeld | 9.29M |
| Aksjonærenes egenkapital | 2.85M |
| Netto varige driftsmidler | 2.85M |
Kontantstrøm
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
| Kontantstrøm fra drift (TTM) | -31.05M |
| Kapitalutgifter (TTM) | 816.10K |
| Fri kontantstrøm (TTM) | -31.84M |
| Utbetalt utbytte (TTM) | 0.00 |
Finansielle inntekter
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
| Egenkapitalavkastning | -1121.97% |
| Avkastning på eiendeler | -263.03% |
| Avkastning på investert kapital | -993.24% |
| Kontantavkastning på investert kapital | -990.63% |
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 0.23 |
| Daglig høy | 0.23 |
| Daglig lav | 0.22 |
| Daglig volum | 474K |
| Tidenes høyeste | 1835.63 |
| 1 år analytikerestimat | 0.42 |
| Beta | 1.29 |
| EPS (TTM) | -0.21 |
| Utbytte per aksje | - |
| Ex-div dato | - |
| Neste dato for resultatpresentasjon | 29 Mar 2023 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ADMP | S&P500 | |
| Nåværende prisfall fra toppnotering | -99.99% | -13.68% |
| Høyeste prisfall | -99.99% | -56.47% |
| Dato for høyeste fall | 24 Oct 2022 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -80.26% | -11.49% |
| Gj.snittlig tid til ny topp | 252 days | 13 days |
| Maks tid til ny topp | 5717 days | 1805 days |
SELSKAPSOPPLYSNINGER
Markedsverdi
33.01M
Markedsverdi kategori
Small-cap
Beskrivelse
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Ansatte
15
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Dennis J. Carlo
Land
USA
By
San Diego
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Q3 2022 Earnings Call Transcript November 14, 2022 Operator: Good afternoon, ladies and gentlemen, and welcome to the Adamis Pharmaceuticals’ Third Qua...
29. desember 2022
Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ETSAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopha...
14. november 2022
SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdo...
7. november 2022
Adamis Pharmaceuticals Corp (NASDAQ: ADMP) has initiated a process to explore a range of strategic and financing alternatives. The move follows the recently announced halting of the company's Phase 2/...
4. oktober 2022
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in va...
3. oktober 2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19 infe...
21. september 2022
Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo Indep...
21. september 2022
The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects Independent Data Monitoring Board to review interim data from approximately 200 initial subjects SAN DIEGO, Sept...
12. september 2022
Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announce...
12. august 2022
Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ETSAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopha...
10. august 2022
Neste side